OTCMKTS:RGBP

Regen BioPharma (RGBP) Stock Price, News & Analysis

0.61
-0.05 (-7.58%)
(As of 05:18 PM ET)
Today's Range
0.58
0.64
50-Day Range
0.57
0.91
52-Week Range
0.40
2.55
Volume
2,294 shs
Average Volume
16,656 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RGBP stock logo

About Regen BioPharma Stock (OTCMKTS:RGBP)

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.

RGBP Stock Price History

RGBP Stock News Headlines

Missed NVDA? Buy this AI stock NOW
After Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.
RGBPP Regen BioPharma, Inc. PFD SER A NEW
Missed NVDA? Buy this AI stock NOW
After Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin.
Regen BioPharma Inc. Non-Cum. Pfd. Series A
See More Headlines
Receive RGBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regen BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:RGBP
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. David Raymond Koos DBA (Age 63)
    Ph.D., Chairman, CEO, President, Secretary & Treasurer
    Comp: $10.05k

RGBP Stock Analysis - Frequently Asked Questions

Are investors shorting Regen BioPharma?

Regen BioPharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 4,500 shares, an increase of 400.0% from the March 31st total of 900 shares. Based on an average daily trading volume, of 37,100 shares, the days-to-cover ratio is presently 0.1 days.
View Regen BioPharma's Short Interest
.

When did Regen BioPharma's stock split?

Regen BioPharma's stock reverse split on the morning of Monday, March 6th 2023. The 1-1500 reverse split was announced on Monday, March 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Regen BioPharma?

Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:RGBP) was last updated on 5/6/2024 by MarketBeat.com Staff

From Our Partners